Cargando…
A retrospective characterization of worsening renal function in patients with acute decompensated heart failure receiving nesiritide
Nesiritide is approved by Food and Drug Administration (FDA) for the treatment of patients with acute decompensated heart failure (ADHF) due its ability to rapidly reduce cardiac filling pressures and improve dyspnea. Numerous studies have shown that renal dysfunction is associated with unfavorable...
Autores principales: | Starr, Jessica A., Nappi, Jean M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centro de Investigaciones y Publicaciones Farmaceuticas
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139050/ https://www.ncbi.nlm.nih.gov/pubmed/25143796 |
Ejemplares similares
-
Outcomes of patients hospitalized for acute decompensated heart failure: does nesiritide make a difference?
por: Carroll, Richard J, et al.
Publicado: (2007) -
Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF)
por: Ezekowitz, Justin A, et al.
Publicado: (2016) -
Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials
por: Gong, Bojun, et al.
Publicado: (2016) -
Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial
por: Abualnaja, Seraj, et al.
Publicado: (2015) -
The Dose-Dependent Effect of Nesiritide on Renal Function in Patients with Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Xiong, Bo, et al.
Publicado: (2015)